Q-POC

Product Description

Q-POC is a solar-powered or wind-up handheld tool designed to diagnose, manage, monitor, and track infections and drug resistance. DNA-based diagnostics can be performed at point-of-care in 10-20 minutes with Q-POC. The device also includes GPS-enabled epidemiological surveillance. Q-POC is currently in a prototype stage and is expected to be commercialized soon. Single use test cartridges are being developed for Warfarin dosage, malaria and drug resistance, hospital acquired infections, and tumor profiling.)

Market Suggested Retail Price

$1,000.00

Target Users (Target Impact Group)

Distributors / Implementing Organizations

Currently unknown, but QuantuMDx is partnered with several NGOs, including FIND, the Bill and Melinda Gates Foundation, the Clinton Foundation, and Global Good.

Manufacturing/Building Method

QuantuMDx has partnered with Integrated Technologies Ltd. to manufacture batches of prototypes and eventually mass produce the final product.

Intellectural Property Type

Patent Protected

User Provision Model

Unknown, as the product has not been commercialized yet.

Distributions to Date Status

N/A, product commercialization expected 2019

Design Specifications

The Q-POC is a portable, battery-operated diagnostics device that can process blood, urine, sputum, tissue, and swabs and delivers results in 10-20 minutes. Results are displayed on a touchscreen and can be stored on the device, sent to a printer, or transferred to a computer or the Cloud via USB or WiFi. Globally distributed Q-POC devices will also geotag and anonymize pathogen data and send to the cloud for real-time disease and drug resistance monitoring. [caption id="attachment_63588" align="alignnone" width="400"] Technical Specifications of Q-POC[/caption] Find the technical specifications here

Technical Support

Provided by the manufacturer

Replacement Components

Testing cassettes

Lifecycle

Unknown

Manufacturer Specified Performance Parameters

QuantuMDx seeks Q-POC can provide personalized medicine, be portable, provide a quick diagnosis, allow for geotagging an creating a network of data.

Vetted Performance Status

99% sensitivity and specificity to molecular results were claimed.

Safety

Unknown

Complementary Technical Systems

None

Academic Research and References

Dunning, L., Kroon, M., Hsiao, N., and Myer, L., 2017, Field Evaluation of HIV Point-of-Care Testing for Early Infant Diagnosis in Cape Town, South Africa, PloS One, 12(12), p. e0189226.

Vu, C., Chan, J., Todaro, M., Skafidas, S., and Kwan, P., 2015, Point-of-Care Molecular Diagnostic Devices: an Overview, Pharmacogenomics, 16(12), pp. 1399-1409.

Dorman, S., 2015, Advances in the Diagnosis of Tuberculosis: Current Status and Future Prospects, The International Journal of Tuberculosis and Lung Disease, 19(5), pp. 504-516.

Basha, I., Ho, E., 2017, Towards Multiplex Molecular Diagnosis—A Review of Microfluidic Genomics Technologies, Micromachines, 8(9), p. 266.

Compliance with regulations

QuantumDx plans to obtain CE marking for all of the Q-POC tests in the short term and then pursue a 510(k) submission with the US Food and Drug Administration.

Other Information

None